GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Viking Therapeutics
Viking Therapeutics, a biotech company, is riding high on hopes for its drugs to treat obesity and metabolic diseases. The stock price reflects high volatility associated with clinical trial results in one of the hottest areas of pharmaceuticals.
Share prices of companies in the market segment - Neuro
Viking Therapeutics is a biotech company developing drugs to treat obesity. We classify it in the pharmaceuticals sector (neurology and metabolism), and the chart below reflects the general trends and the significant investor interest in this area.
Broad Market Index - GURU.Markets
Viking Therapeutics is a biopharmaceutical company developing drugs to treat metabolic and endocrine diseases, including obesity. Its promising pipeline makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Viking is outperforming the overall market.
Change in the price of a company, segment, and market as a whole per day
VKTX - Daily change in the company's share price Viking Therapeutics
Viking Therapeutics shares, like many biotech companies, are highly volatile. Change_co measures the market's reaction to clinical trial data, particularly in the hot area of obesity treatment. This metric is an indispensable component for building complex risk assessment models and potential breakthroughs on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Viking Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with VKTX, which focuses on treating obesity and liver disease, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Viking Therapeutics is a biopharmaceutical company developing drugs to treat metabolic and endocrine diseases, including obesity. This is one of the hottest and most volatile areas in pharmaceuticals. The chart below reflects the average fluctuations in this industry, providing context for evaluating Viking's stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Viking Therapeutics
Viking Therapeutics is a biotech star developing drugs for the treatment of obesity and liver disease. Its year-over-year share price performance, shown in the chart, directly reflects breakthrough clinical data, which has been highly praised by investors.
Annual dynamics of market capitalization of the market segment - Neuro
Viking Therapeutics, Inc. is a clinical-stage biotech company developing drugs to treat metabolic diseases, including obesity. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its drugs in this highly competitive field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Viking Therapeutics is one of the hottest stories in biotech, focused on developing anti-obesity drugs. Its stock price has nothing to do with the economy, but is driven by news of clinical trials. The chart reflects investors' high hopes for a new blockbuster that could change the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Viking Therapeutics
The value of Viking Therapeutics, a biopharmaceutical company, is speculative. The monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its drugs for the treatment of obesity and metabolic diseases, the success of which determines its ability to compete in this vast market.
Monthly dynamics of market capitalization of the market segment - Neuro
Viking Therapeutics develops drugs to treat metabolic and endocrine diseases, including obesity. Like many biotech companies, its valuation depends on the success of clinical trials. The biotech sector performance chart reflects overall investor sentiment towards the industry, allowing one to assess Viking's potential in the context of market expectations.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Viking Therapeutics is a biotech company developing drugs to treat metabolic diseases, including obesity and NASH. This is one of the hottest topics in pharma. Given the market trends shown in the chart, Viking shares are living in a world of clinical trial news, where positive data can trigger explosive growth, defying any market downturn.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Viking Therapeutics
Shares of Viking Therapeutics, a biopharmaceutical company, move in sync with clinical trial news. Weekly price movements reflect investor expectations for their drugs for metabolic and neurological diseases. The chart below illustrates how any news about trial progress can trigger sharp short-term fluctuations.
Weekly dynamics of market capitalization of the market segment - Neuro
How does Viking Therapeutics' performance compare to the broader biotech sector? This chart compares the company's weekly stock price movements with the overall trend. This helps us understand whether its sharp move, driven by obesity treatment news, is a unique event or a reflection of overall investor sentiment on this hot topic.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases. This chart compares its weekly volatility with the market. It shows how its shares are driven by expectations of clinical trial results, ignoring macroeconomic considerations.
Market capitalization of the company, segment and market as a whole
VKTX - Market capitalization of the company Viking Therapeutics
Viking Therapeutics' valuation on the chart reflects investors' high hopes for its obesity and metabolic disease treatments, particularly MASH. The company's market cap soared on the back of positive trial data. This trend shows how the market views its chances in the race to capture the multibillion-dollar weight loss drug market.
VKTX - Share of the company's market capitalization Viking Therapeutics within the market segment - Neuro
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases, including obesity and liver disease. Its share of its sector market cap reflects the enormous potential of its candidates. The chart shows how investor expectations for clinical trials in these hot markets shape its value.
Market capitalization of the market segment - Neuro
This chart is the pulse of the biotech sector focused on metabolic diseases and neuroscience. Viking Therapeutics is one of the most prominent companies in this field. The dynamics on the chart reflect the enormous investor expectations surrounding its promising drugs for the treatment of obesity and NASH.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a visualization of the market valuation of a breakthrough in the treatment of metabolic diseases like obesity. Viking Therapeutics' market cap has soared on the back of expectations for its experimental drugs. The chart shows how a biotechnology company targeting one of the most pressing health problems can generate colossal value.
Book value capitalization of the company, segment and market as a whole
VKTX - Book value capitalization of the company Viking Therapeutics
The graph below shows Viking Therapeutics' scientific foundation. Its line reflects the value of intellectual property for drugs treating metabolic and neurological disorders, as well as cash reserves for clinical trials. An upward trend on the graph indicates progress in research, the company's primary asset.
VKTX - Share of the company's book capitalization Viking Therapeutics within the market segment - Neuro
Viking Therapeutics, as a biotech company, focuses on research. Its tangible assets are laboratories and scientific equipment, not factories. The chart shows its share of physical infrastructure, which is the basis for developing new treatments for metabolic and neurological diseases.
Market segment balance sheet capitalization - Neuro
Viking Therapeutics is a clinical-stage biotech company. Its value is created in labs, not factories. It's a "lightweight" model based on intellectual capital. The chart below shows how much the biopharmaceutical industry relies on tangible assets versus intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Viking Therapeutics' balance sheet is focused on clinical trials of promising drugs for the treatment of metabolic diseases such as obesity. The book value chart shows the amount of financial resources devoted to this hot area of pharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Viking Therapeutics
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases, including obesity. It has no revenue or assets other than cash. Its massive market capitalization is a bet on the success of its drugs in one of the hottest areas of pharmacology. The chart is a pure indicator of market expectations.
Market to book capitalization ratio in a market segment - Neuro
Viking Therapeutics is a biotech company developing drugs to treat metabolic diseases such as obesity. It has no commercial products. Its huge market capitalization reflects investors' bet on the success of its clinical trials. The chart clearly demonstrates this premium on expectations.
Market to book capitalization ratio for the market as a whole
Viking Therapeutics is a biotech company developing drugs for the treatment of metabolic and endocrine diseases. The chart illustrates the market's enormous anticipation of this potential blockbuster in obesity treatment. Its market capitalization, boosted by research data, is a clear bet by investors on the future commercial success of its drugs.
Debts of the company, segment and market as a whole
VKTX - Company debts Viking Therapeutics
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases. Being in clinical trials, the company requires significant funding. This chart shows how Viking raises capital to advance its promising, but expensive, developments through all phases of testing.
Market segment debts - Neuro
Viking Therapeutics is a clinical-stage biopharmaceutical company specializing in metabolic and endocrine diseases. Like many biotech companies without revenue, it relies on external funding for research. This chart illustrates the general norms for the pharmaceutical sector, highlighting its high-risk R&D funding model.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Viking Therapeutics
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases. Being in clinical trials, it has no recurring revenue. This chart shows how Viking funds its long-term, capital-intensive research, which is key to assessing its prospects.
Market segment debt to market segment book capitalization - Neuro
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine disorders, including liver disease. This chart compares the debt it raised to fund expensive clinical trials to the total market capitalization of the entire neuroscience pharmaceutical sector, demonstrating the scale of its scientific ambitions.
Debt to book value of all companies in the market
Viking Therapeutics develops drugs to treat common metabolic diseases. This chart compares the debt it incurred for large-scale research with the total book value of the entire economy. It shows how significant the company's financial stakes are in the success of its developments, relative to the overall stock market.
P/E of the company, segment and market as a whole
P/E - Viking Therapeutics
This chart for Viking Therapeutics, a biotech developing drugs to treat metabolic and neurological diseases, reflects investor expectations. Its value is determined not by current profits, but by the potential of its drug candidates to become breakthroughs in their field. This metric is a measure of the company's hopes for clinical success.
P/E of the market segment - Neuro
This metric represents the average valuation for the biotech sector in which Viking Therapeutics operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark.
P/E of the market as a whole
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases such as obesity and nonalcoholic steatohepatitis (NASH). The company operates in a large and growing market. This chart shows how the overall market views the biotech sector and its potential blockbusters.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Viking Therapeutics
Viking Therapeutics is a biopharmaceutical company developing drugs for the treatment of metabolic and endocrine disorders, including liver disease. This chart reflects high investor expectations for the success of clinical trials, demonstrating the market's confidence in the potential of the company's drugs to become blockbusters.
%20P%2FE%20Viking%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Viking-Therapeutics&v=1772688609219 "Chart of the company's future (projected) P/E Viking Therapeutics")
Future (projected) P/E of the market segment - Neuro
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for metabolic and endocrine disorders. Its lead candidates target nonalcoholic steatohepatitis (NASH) and obesity. This chart shows overall market sentiment toward the biotech sector, helping to assess Viking Therapeutics' potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772688609232 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases, including obesity and NASH. Its value reflects its expected success in a highly competitive but potentially enormous field. Viking's valuation is determined by trial data, not by general market forecasts.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772688609247 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Viking Therapeutics
Viking Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of drugs for the treatment of metabolic and endocrine diseases. Its financial results reflect significant R&D expenditures. This chart illustrates the company's investment in the development of potentially breakthrough drugs.
Profit of companies in the market segment - Neuro
Viking Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat metabolic and endocrine diseases, such as obesity and nonalcoholic steatohepatitis (NASH). This chart reflects the profitability of its segment. Viking's success could bring breakthrough treatments to market, making it one of the most talked-about companies in this field.
Overall market profit
Viking Therapeutics is a biopharmaceutical company developing drugs for the treatment of metabolic and endocrine diseases, including the popular MASH (non-alcoholic steatohepatitis) drug. Its value depends on the success of clinical trials. This chart shows general market cycles, while Viking's shares are driven by lab news and the potential of its developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Viking Therapeutics
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic and endocrine diseases, including obesity. This chart reflects the high expectations of analysts regarding the potential of its drug candidates in one of the largest and fastest-growing markets in pharmaceutical history.
%20profit%20of%20the%20company%20Viking%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Viking-Therapeutics&v=1772688609378 "Graph of future (projected) profit of the company Viking Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for metabolic and endocrine disorders. This chart shows revenue projections for the neuroscience segment. It reflects the high interest in potential breakthroughs in the treatment of diseases such as nonalcoholic steatohepatitis (NASH).
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772688609476 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases, including obesity. This sector is attracting significant investor attention. The overall profit forecast shown here influences overall risk appetite. A positive market makes it easier for Viking to raise capital to complete large-scale clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772688609481 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Viking Therapeutics
Viking Therapeutics is a biotechnology company developing drugs for the treatment of metabolic and endocrine diseases, including obesity. Without revenue, the P/S ratio is not applied, but the company's future valuation will depend entirely on the success of clinical trials and the subsequent commercialization of its promising candidates.
P/S market segment - Neuro
Viking Therapeutics is a clinical-stage biotech developing drugs for the treatment of metabolic and endocrine diseases, including obesity and NAFLD. Its high valuation is based on the enormous potential of these markets. The chart reflects investor expectations for clinical trial results and future commercial success.
P/S of the market as a whole
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases, including obesity. The company doesn't yet have revenue, but its valuation is high due to its huge potential market. This chart, showing the valuation of companies with real revenues, highlights Viking's bet on a future pharmaceutical blockbuster.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Viking Therapeutics
Viking Therapeutics is a biotech company developing drugs to treat metabolic diseases, including obesity. Its valuation has soared on expectations of success in this hot field. This chart reflects investors' high hopes for future multibillion-dollar sales of its drugs if they prove successful and competitive.
%20P%2FS%20Viking%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Viking-Therapeutics&v=1772688609640 "The graph of the company's future (projected) P/S Viking Therapeutics")
Future (projected) P/S of the market segment - Neuro
Viking Therapeutics is a clinical-stage biopharmaceutical company specializing in developing treatments for metabolic and endocrine disorders, particularly nonalcoholic steatohepatitis (NASH). This chart shows how the market perceives the enormous, yet risky, future commercial potential of its drugs compared to other companies in the neuroscience sector.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772688609644 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases, including obesity. It operates in one of the most promising markets in the pharmaceutical industry. This chart shows aggregate market expectations for future revenue, and VKTX exemplifies how expectations of breakthroughs in treating widespread diseases fuel investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772688609667 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Viking Therapeutics
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders, such as nonalcoholic steatohepatitis (NASH). Revenue is either absent or minimal in this chart, as the company has no commercial products and its revenue may come from royalties.
Sales of companies in the market segment - Neuro
Viking Therapeutics is a biotech company developing drugs for the treatment of metabolic and endocrine diseases. At this stage, its revenue, if any, is likely derived from licensing agreements. This chart allows investors to see the financial support from partners, confirming the potential of its developments.
Overall market sales
Viking Therapeutics is a biopharmaceutical company developing drugs to treat metabolic and endocrine diseases, such as obesity. Its valuation is dependent on clinical trial results. This market summary chart is irrelevant to assessing Viking's potential, which is determined solely by scientific data and the size of the target market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Viking Therapeutics
Viking Therapeutics is a biopharmaceutical company developing drugs to treat metabolic and endocrine diseases, including obesity. Its revenue forecast is based on expectations of successful clinical trials. This chart reflects the intense interest and speculative bets of analysts on a potential blockbuster in the weight loss market.
%20sales%20of%20the%20company%20Viking%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Viking-Therapeutics&v=1772688609749 "Schedule of future (projected) sales of the company Viking Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Viking Therapeutics is a biopharmaceutical company developing drugs for the treatment of metabolic and endocrine diseases. This chart shows projected revenues for the entire neuroscience and metabolic segments. It allows one to assess whether analysts see growth potential in these markets, which is crucial for the future commercial success of Viking's drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772688609756 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases, including obesity. Its valuation depends on the success of clinical trials. However, the overall market environment, reflected in the chart, is critical for attracting investment. A positive environment facilitates the funding of expensive R&D programs in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772688609784 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Viking Therapeutics
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases. This chart reflects the company's current status in clinical development. It shows the company's investment in research, and its future ability to generate revenue depends entirely on the success of its developments.
Market segment marginality - Neuro
Viking Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of metabolic and endocrine diseases. This chart reflects the enormous potential of its developments. If successful, the company's future profitability could significantly exceed average levels, given the scale of the markets it targets.
Market marginality as a whole
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases, including obesity and liver disease. It is at the center of one of the hottest topics in pharmaceuticals. This chart of overall market returns doesn't reflect the enormous potential investors see in the weight loss drug sector.
Employees in the company, segment and market as a whole
Number of employees in the company Viking Therapeutics
Viking Therapeutics is a biotech company developing drugs for the treatment of metabolic and endocrine diseases. Currently, its team is small and consists of scientists and clinical trial specialists. A sharp increase on this chart in the future will indicate successful advancement of the drugs into late-stage trials.
Share of the company's employees Viking Therapeutics within the market segment - Neuro
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on treating metabolic and endocrine diseases. This chart highlights its scientific potential. It reflects the proportion of talented biochemists and researchers working on developing next-generation drugs for conditions such as obesity and diabetes that Viking brings together.
Number of employees in the market segment - Neuro
Viking Therapeutics is a biopharmaceutical company developing drugs to treat metabolic and endocrine diseases. This chart illustrates its work in neuroscience and metabolism. The growing number of scientists in this field indicates breakthroughs in the treatment of conditions such as obesity and liver disease, a key area of research for Viking.
Number of employees in the market as a whole
Viking Therapeutics is a biopharmaceutical company developing drugs for the treatment of metabolic and endocrine diseases. The growth of its scientific team is an indicator of progress in clinical trials and investor confidence in the potential of its developments. This is an example of creating knowledge-based jobs at the forefront of medical science.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Viking Therapeutics (VKTX)
Viking Therapeutics is a clinical-stage biotech company developing drugs for the treatment of metabolic and endocrine diseases. Their stratospheric market capitalization is based solely on investor expectations for their future drugs. This timeline will be astronomical for them, as their billion-dollar market value is based on a small staff of scientists.
%20of%20the%20company%20Viking%20Therapeutics%20(VKTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Viking-Therapeutics-VKTX&v=1772688610023 "Chart of market capitalization per employee (in thousands of dollars) of the company Viking Therapeutics (VKTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Viking Therapeutics is a clinical-stage biotech whose drug candidates (especially in the areas of metabolism and MASH/obesity) are generating tremendous interest. Its entire value lies in its R&D. This chart shows the industry average, demonstrating the enormous (and speculative) market value investors are placing on the potential of this research team.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772688610029 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Viking Therapeutics is a biotech company developing drugs to treat metabolic and endocrine diseases. The company's value lies in its scientific research. This chart shows how highly investors value the team's potential to create a new, effective drug that could become a blockbuster.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772688610043 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Viking Therapeutics (VKTX)
Viking Therapeutics is a clinical-stage biotech company targeting metabolic diseases, including obesity (a competitor to Mounjaro/Ozempic) and NAFLD. This chart is deeply negative. It shows how much capital is being burned per scientist in this ultra-competitive race for a multi-billion dollar market.
%20Chart%20Viking%20Therapeutics%20(VKTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Viking-Therapeutics-VKTX&v=1772688610058 "Company Profit Per Employee (in thousands of dollars) Chart Viking Therapeutics (VKTX)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Viking Therapeutics is a clinical-stage biotech company developing drugs (GLP-1) for the treatment of *obesity*. This chart shows the benchmark for the "Biotech" sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies are burning through money on R&D (clinical trials).
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772688610064 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Viking Therapeutics is a biotech company developing drugs to treat obesity and fatty liver disease (MASH), one of the hottest sectors in pharma. This is R&D. This chart shows the average market profit per employee. It helps understand how the biotech sector (metabolic diseases) compares to average employee profitability.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772688610072 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Viking Therapeutics (VKTX)
Viking Therapeutics is a biotech company with drugs in clinical trials. This graph shows minimal or no revenue per employee. It reflects the period of investment in research. Positive trial results and potential drug approval could lead to exponential growth of this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Viking-Therapeutics-VKTX&v=1772688610076 "Sales chart per company employee Viking Therapeutics (VKTX)")
Sales per employee in the market segment - Neuro
Viking Therapeutics is a clinical-stage biotech company focused on treating metabolic diseases (e.g., MASH). Revenue is minimal. This chart shows the average revenue per employee in the segment, which is a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of VKTX's staff.
Sales per employee for the market as a whole
Viking Therapeutics (VKTX) is a biotech company developing drugs to treat metabolic diseases (such as obesity). This is one of the hottest sectors. Like other biotechs (CRNX, XENE), this metric is currently irrelevant (there is no revenue). Investors are betting on a future blockbuster that will explode this chart.
Short shares by company, segment and market as a whole
Shares shorted by company Viking Therapeutics (VKTX)
Viking Therapeutics is a biotech company whose reputation is built on developing drugs to treat metabolic diseases, primarily obesity. They compete with giants Novo Nordisk and Eli Lilly. This chart shows the odds that they will lose this race. The bears believe their drug won't be able to outperform existing blockbusters.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Viking-Therapeutics-VKTX&v=1772688610096 "Short Shares Chart for the Company Viking Therapeutics (VKTX)")
Shares shorted by market segment - Neuro
Viking Therapeutics is a clinical-stage biotech company developing drugs to treat metabolic disorders, including obesity (a competitor to Ozempic). This chart highlights pessimism in the biotech sector. The rise in short positions may reflect concerns about the extreme competition in the obesity drug market, where Viking faces competition from pharma giants.
Shares shorted by the overall market
Viking Therapeutics is a clinical-stage biotech company specializing in metabolic and endocrine diseases, including obesity (GLP-1 analogs). This chart measures overall market pessimism. For companies without revenue, dependent on investor risk appetite, rising fear is a death sentence. It means raising funds for expensive clinical trials becomes extremely difficult.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Viking Therapeutics (VKTX)
Viking Therapeutics is a biotech company developing drugs to treat metabolic diseases (MASH, obesity), a competitor of LLY/NVO. The stock is extremely volatile. A chart above 70 may reflect euphoria following positive trial data. A range below 30 is associated with setbacks or concerns about competition.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Viking-Therapeutics-VKTX&v=1772688610132 "RSI 14 indicator chart for the company's stock Viking Therapeutics (VKTX)")
RSI 14 Market Segment - Neuro
Viking Therapeutics is a biopharmaceutical company developing drugs for the treatment of metabolic and endocrine diseases. Its candidates in the fields of MASH (liver disease) and obesity are generating considerable interest. This chart shows the overall "temperature" in the hot biotech obesity sector. It helps separate the dynamics of VKTX from the general hype surrounding this class of drugs.
RSI 14 for the overall market
Viking Therapeutics (VKTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VKTX (Viking Therapeutics)
Viking Therapeutics (VKTX) is a biopharmaceutical company developing drugs to treat metabolic and endocrine diseases. Its lead candidate targets obesity and MASH (hepatitis). This chart shows the average analyst forecast, reflecting their high expectations for VKTX's clinical data in the race for the multibillion-dollar weight loss drug market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VKTX-Viking-Therapeutics&v=1772688610153 "A chart showing analyst consensus forecasts for the expected stock price. VKTX (Viking Therapeutics)")
The difference between the consensus estimate and the actual stock price VKTX (Viking Therapeutics)
Viking Therapeutics is a biotech company at the forefront of the GLP-1 race. They are developing oral drug candidates for the treatment of obesity and MASH. This chart shows the gap between the current market valuation and the analyst target price, highlighting the enormous potential experts see in their developments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VKTX-Viking-Therapeutics&v=1772688610173 "A chart showing the difference between the consensus forecast and the actual stock price. VKTX (Viking Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Viking Therapeutics is a biotech company at the epicenter of the 21st century's "gold rush"—developing drugs to treat obesity (GLP-1). This chart shows analysts' overall expectations for the entire neuroscience/metabolism sector. It reflects whether experts believe there is room for new players in this market.
Analysts' consensus forecast for the overall market share price
Viking Therapeutics (VKTX) is a hot biotech, a leader in the race for obesity drugs (GLP-1), competing with Lilly and Novo. This chart, reflecting expert expectations, is a proxy for risk appetite. If the market is pessimistic, investors may take profits even on hot stocks, wary of R&D risks.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Viking Therapeutics
Viking Therapeutics is a biotech company at the epicenter of the obesity treatment gold rush. Their main asset is an experimental drug that directly competes with mega-blockbusters Ozempic/Wegovy. This chart is a pure indicator of biotech expectations. It aggregates their clinical trial data and market confidence in their chances in this multi-billion-dollar race.
AKIMA Market Segment Index - Neuro
Viking Therapeutics (VKTX) is a biotech at the epicenter of the GLP-1 race; the company has no revenue but is developing some of the most anticipated competitors for obesity (like Ozempic) and liver disease (NASH). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does VKTX's R&D rate differentiate it from the average pharma company?
The AKIM Index for the overall market
Viking Therapeutics is a clinical-stage biotech company, a leader in the race to develop an obesity drug (competitor to Ozempic) and MASH (liver). This is a high-risk scientific bet. This chart, reflecting the market average, is an indicator of risk appetite. It shows the macro backdrop for funding such companies.
